Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.17+1.58 (+23.98%)
At close: 04:00PM EDT
8.15 -0.02 (-0.24%)
After hours: 05:41PM EDT
Advertisement

Immunovant, Inc.

320 West 37th Street
6th Floor
New York, NY 10018
United States
917 580 3099
https://immunovant.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees124

Key Executives

NameTitlePayExercisedYear Born
Dr. Frank M. Torti M.B.A., M.D., MBAExec. Chairperson of the Board94.11kN/A1979
Dr. Peter Salzmann M.B.A., M.D.CEO & Director979.96kN/A1968
Ms. Eva Renee Barnett M.B.A.Chief Financial Officer534.98kN/A1980
Dr. William L. Macias M.D., Ph.D.Chief Medical Officer4.85MN/A1958
Dr. Julia G. Butchko Ph.D.Chief Devel. & Technology OfficerN/AN/A1971
Tom Dorney M.B.A., M.S.Director of Investor Relations & StrategyN/AN/AN/A
Mr. Mark S. LevineChief Legal Officer & Corp. Sec.N/AN/A1973
Ms. Lauren Schrier M.B.A.VP of MarketingN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Corporate Governance

Immunovant, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 10. The pillar scores are Audit: 6; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement